Lymphocytes travel throughout the body to carry out immune surveillance and participate in inflammatory reactions. Their path takes them from blood through tissues into lymph and back to blood. Molecules that control lymphocyte recruitment into extralymphoid tissues are well characterized, but exit is assumed to be random. Here, we showed that lymphocyte emigration from the skin was regulated and was sensitive to pertussis toxin. CD4 + lymphocytes emigrated more efficiently than CD8 + or B lymphocytes. T lymphocytes in the afferent lymph expressed functional chemokine receptor CCR7, and CCR7 was required for T lymphocyte exit from the skin. The regulated expression of CCR7 by tissue T lymphocytes may control their exit, acting with recruitment mechanisms to regulate lymphocyte transit and accumulation during immune surveillance and inflammation.
Naive T cells preferentially recirculate between blood and secondary lymphoid tissues, entering lymph nodes from the blood by crossing high endothelial venules [1] [2] [3] . Memory and effector T cells, unlike naive T cells, can migrate efficiently into nonlymphoid tissues and into sites of inflammation and infection 4 , subsequently entering afferent lymphatic vessels and traveling to local lymph nodes in the afferent lymph 3, 5, 6 . In parabiotic mouse models, endogenous memory T cells in most peripheral tissues reach equilibrium with immigrating bloodborne donor T cells within a week, suggesting that there is rapid turnover of T cells in peripheral tissues 7 . Indeed, blood-to-lymph migration through peripheral tissues such as the skin is very dynamic, with a peak transit time for lymphocytes of approximately 24 h (ref. 8) . Classic studies of recirculation in sheep have demonstrated that 10% of the total lymphocytes 9 and most memory-effector lymphocytes 3 entering a given lymph node do so through the afferent lymph. Collectively, these studies indicate that lymphocyte exit from tissues and migration via afferent lymph into the draining nodes is a critical homeostatic migration pathway for memory and effector T cells.
The afferent lymph from tissues such as the skin contains mainly memory CD4 + T cells and few B cells 5, 6, 10, 11 , which mirrors the preferential recruitment and accumulation of CD4 + T cells relative to B cells in peripheral tissues. That finding and the fact that erythrocytes can enter the afferent lymph when injected into tissues led to the idea that lymphocyte migration into the afferent lymph is a passive and random process determined mainly by fluid flow 12 . That idea contrasts with the tight control of the various other steps of lymphocyte recirculation, from the multicomponent combinatorial control of recruitment of circulating lymphocytes from the blood 13 to the regulation of lymphocyte exit from lymph nodes by cell-cell interactions and sphingosine 1-phosphate and its receptors 14, 15 .
To directly assess the selectivity of lymphocyte exit from nonlymphoid tissues, we have established an experimental system in which the migration of adoptively transferred lymphocytes from subcutaneous tissues into draining lymph nodes is monitored. Our studies show that lymphocyte exit into afferent lymphatics is a tightly regulated process under control of the chemokine receptor CCR7.
RESULTS

Tissue exit is nonrandom
Earlier studies assumed that tissue exit is a random process and that lymphocytes in the interstitium could passively enter afferent lymph 12 .
To study lymphocyte exit from a peripheral site, we labeled mouse splenocytes with 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) or the PKH26 red fluorescent cell linker (PKH26), injected them subcutaneously into the footpads of recipient mice and evaluated the number and phenotype of cells that migrated into the draining popliteal lymph nodes (Fig. 1) . The frequency of migrated cells increased from 3 to 18 h; we chose a 12-hour time point for most subsequent experiments because at that time after injection, the blood, spleen and contralateral lymph nodes remained essentially devoid of transferred cells (data not shown), indicating that cells that had migrated via the afferent lymph and reached the draining lymph node had not yet entered the circulation.
If lymphocyte exit were random, then the cells recovered from the draining lymph node would have the same cellular composition as the injected population. Instead, populations recovered from the lymph node were considerably enriched for CD4 + T cells compared with the injected population (Fig. 1a) . Naive (CD44 lo CD45RB hi ) CD4 + T cells migrated somewhat better than memory (CD44 hi CD45RB lo ) CD4 + T cells, as indicated by a slight enrichment in naive CD4 + T cells of the migrated fraction compared with the injected cells (Fig. 1b) . Although there was considerable variability in the overall numbers of migrated cells recovered from the draining lymph nodes of individual mice, CD4 + T cells consistently exited the footpads more efficiently than CD8 + T cells or B cells (Fig. 1c, left) . CD4 + T cells migrated, on average, about 12-fold and 3-fold more efficiently than CD8 + T cells and B cells, respectively (Fig. 1c, right) . We conclude that exit from peripheral sites is a selective process.
Tissue exit requires G ai protein-coupled receptors To determine whether T cell exit from peripheral tissues and migration into the draining lymph node through the afferent lymph is an active process that involves chemoattractant receptor signaling, we treated mononuclear cells from spleen with pertussis toxin (PTX), which irreversibly modifies Ga i proteins and prevents most chemotactic responses. We labeled PTX-treated splenocytes with CFSE and injected them into the footpads of recipient mice. Concurrently, we injected equal numbers of 'mock-treated' PKH26-labeled splenocytes into the contralateral footpads and assessed migration to the draining lymph nodes 12 h later. Pretreatment with PTX almost completely inhibited lymphocyte migration to the draining lymph node (Fig. 2) . We obtained the same result when the dyes were reversed (data not shown). At later time points after transfer (18-24 h), infrequent untreated cells, but no PTX-treated cells, could be detected in the recipients' blood (data not shown). Cells reisolated from the injected footpad (whether treated with PTX or not) excluded propidium iodide and failed to bind annexin V, excluding the possibility of a general effect on cell viability. We conclude that tissue exit is a regulated, nonrandom, Ga i -coupled receptor signaling-dependent process that probably involves chemoattractant receptors.
Impaired tissue exit by CCR7-deficient lymphocytes
Having established a function for G protein signaling in tissue exit, we next tested whether CCR7 expression controls lymphocyte exit from peripheral tissues. To evaluate the migration of CCR7-deficient (Ccr7 À/À ) cells, we injected a mixture of CFSE-labeled splenic lymphocytes from Ccr7 À/À mice 16 and PKH26 + wild-type lymphocytes or a control mixture of CFSE-and PKH26-labeled lymphocytes from wild-type mice into the footpads of recipient mice. At 12 h after transfer, equal numbers of CFSE + and PKH26 + wild-type cells reached the draining lymph nodes (Fig. 3a, left) . In contrast, CFSE + Ccr7 À/À cells were much less frequent in the draining lymph node (Fig. 3a,  right) : the migration of Ccr7 À/À CD4 + T cells was reduced by 90% ( Fig. 3b) and CCR7 deficiency inhibited the migration of CD45RB hi naive and CD45RB lo memory CD4 + cells to the same extent (Fig. 3b) . The relatively inefficient exit of CD8 + T cells and B cells from the skin (Fig. 1) was also mostly CCR7 dependent (Fig. 3b) . These differences in migration between Ccr7 À/À and wild-type lymphocyte subsets were apparent at 3 h, 6 h and 9 h after injection as well, although fewer cells had reached the lymph nodes at those earlier time points (data not shown). As noted for wild-type lymphocytes, at those time points and in most experiments at 12 h after injection, no Ccr7 À/À cells were detected in the spleen, the site of preferential localization of Ccr7 À/À lymphocytes 16 , or in the contralateral lymph nodes, and no cells were detected in blood (data not shown). These observations indicate that CCR7 is a key regulator of T lymphocyte exit from the skin and subsequent migration into the draining lymph node.
Transduced CCR7 restores the exit of Ccr7 À/À T cells The impaired migration of Ccr7 À/À lymphocytes from the skin to the draining lymph node strongly suggested that CCR7 mediates T cell exit from peripheral sites. However, T cells from Ccr7 À/À mice could be abnormal because of their development in an organism with disrupted lymphoid architecture. Therefore, we sought to determine if reintroducing CCR7 could restore the tissue exit of Ccr7 À/À T cells. We transduced Ccr7 À/À CD4 + T cells with a retroviral expression vector encoding CCR7 and an internal ribosomal entry site-green fluorescent protein (IRES-GFP) cassette (CCR7 vector) or with a control vector encoding only GFP. To confirm expression of surface CCR7, we tested cell binding to a fusion protein consisting of the mouse CCR7 ligand CCL19 fused to human immunoglobulin G 17 (CCL19-Ig).
Wild-type T cells had high expression of surface CCR7 (Fig. 4a, left) , whereas Ccr7 À/À T cells, whether transduced with the control vector or not, failed to bind CCL19-Ig (Fig. 4a, middle) . Ccr7 À/À T cells transduced with the CCR7 vector (GFP + ) bound CCL19-Ig (Fig. 4a, right) , although less efficiently than wild-type cells. Consistent with the CCR7 surface expression, wild-type T cells migrated efficiently toward the CCR7 ligand CCL21 in an in vitro chemotaxis assay, whereas Ccr7 À/À T cells responded only when transduced with the CCR7 vector (Fig. 4b) . Transduction of cells with the control vector had no influence on the capacity of wild-type or Ccr7 À/À T cells to exit the skin of congenic Thy-1.1 mice (Fig. 4c , left and middle). In contrast, transducing Ccr7 À/À CD4 + T cells with the CCR7 vector rescued their ability to migrate to the draining lymph node (Fig. 4c, right) . We conclude that the migratory defect of Ccr7 À/À T cells is due to their lack of CCR7.
T cells in the afferent lymph express functional CCR7
If physiologically recirculating T cells use CCR7 to exit from peripheral tissue sites, then T cells in the draining afferent lymph should express functional CCR7. To test this prediction, we cannulated the skin draining afferent lymph vessels (proximal to the draining lymph node) of sheep, an animal used in classical recirculation studies. We analyzed CCR7 (CCL19-Ig binding) expression by memory (CD45R À ) and naive (CD45R + ) T cell subsets. Consistent with published reports 3 , almost all CD4 + T cells in afferent lymph draining the skin were of the memory phenotype (Fig. 5a) . Most of these afferent lymph CD4 + T cells bound CCL19-Ig (Fig. 5a ). Memory CD4 + T cells in the blood comprised major populations of CCL19-Igbinding and CCL19-Ig-nonbinding cells, as expected 18, 19 . Almost all afferent lymph CD8 + T cells were also of memory phenotype (CD45R À ), and most of these bound CCL19 as well ( Fig. 5a ; range, 50-89%, mean, 69.8%, from six different experiments). Moreover, in Transwell chemotaxis assays, memory T cells from afferent lymph and from blood migrated efficiently toward the CCR7 ligands CCL21 and CCL19 (Fig. 5b) . Lymph memory T cells showed equal or greater sensitivity toward CCR7 ligands relative to that of blood memory T cells, as indicated by half-maximal responses at lower chemokine concentrations (Fig. 5b ). These data demonstrate that shortly after tissue exit and before arrival at the draining lymph node, memory T cells that recirculate through the skin express CCR7 and are enriched in responsiveness to CCR7 ligands.
DISCUSSION
Lymphocyte recirculation is a highly regulated process, controlling the distribution and targeting of immune cells throughout the body. Migration from the blood into lymphoid as well as peripheral tissues is determined by complex, combinatorially determined events involving multiple molecules that together regulate the tissue access of specialized lymphocyte subsets. The exit of lymphocytes from organized lymphoid tissues into the efferent lymphatics is controlled by distinct mechanisms involving sphingosine 1-phosphate and its receptors 14, 15 . The exit of lymphocytes from peripheral tissue such as the skin, however, has long been assumed to be random 12 . The goal of our study here was to evaluate the selectivity and mechanisms of lymphocyte exit from peripheral tissues. Our findings have shown that lymphocyte exit into afferent lymphatics, far from being random, is controlled by specific chemotactic mechanisms, and that CCR7 is an essential mediator of this process. Memory as well as naive CD4 + T cells exited more efficiently than CD8 + T cells or B cells, but CCR7 was important in each case. The enhanced efficiency of exit into lymph by CD4 + T cells relative to CD8 + T cells or B cells is mirrored in the predominance of CD4 + T cells in afferent lymph 5, 6, 10, 11 . The differential emigration also suggests that additional signals may be required for tissue exit, because CD4 + and CD8 + T cells from mouse spleen have similar CCR7 expression 17 . Additional control mechanisms might include interactions with adhesion molecules expressed by lymphatic endothelium, such as CLEVER-1 (ref. 20) . Our results are in line with published reports that CD4 + have a higher capacity than CD8 + T cells to recirculate from blood through tissues such as the peripheral and mesenteric lymph nodes 21 , intestine and skin 22 . The reason for these T cell subset-specific differences in recirculation remains to be elucidated.
The critical function of CCR7 in T cell recirculation at the stage of exit from peripheral tissues may be considered unexpected, given the idea of CCR7 as a marker for 'central memory T cells' that circulate exclusively through secondary lymphoid organs 18, 23 . However, studies have shown that CCR7 is expressed by T cells that exert immediate effector functions 17, 24, 25 and by many memory-effector T cells that infiltrate extralymphoid tissues, including the skin, synovium and lung 19, 24, 26 .
Moreover, the CCR7 ligand CCL21 is constitutively expressed by lymphatic endothelial cells in extralymphoid tissues [27] [28] [29] , where it mediates the CCR7-dependent migration of mature antigen-presenting dendritic cells into the afferent lymph 16, 28, 30, 31 . CCL21-expressing lymphatics can be visualized immunohistochemically in skin, mainly adjacent to venules involved in lymphocyte recruitment or immediately underlying the epithelium 32, 33 ; thus, they are well positioned to mediate the CCR7-dependent exit of T cells from physiological sites of lymphocyte infiltration. In this context, the efficiency of short-term exit of footpad-injected cells is expected to depend not only on their expression of CCR7 but also on their proximity to these lymphaticrich microenvironments. The distribution of injected cells to the deep connective tissues versus the superficial dermis may thus underlie the relatively low overall efficiency and may also explain the animal-toanimal variability of T cell exit in our experiments. In addition, in normal skin, in the absence of inflammatory stimuli, CCL21 expression by lymphatic endothelial cells is relatively low 32, 33 , perhaps paralleling the low rate of homeostatic lymphocyte recirculation through this site. Notably, the efficiency of CD4 + T cell migration we found (range, 0.3-1.7% of injected cells; mean of five experiments, 0.81%) is similar to that reported for dendritic cells in similar studies (0.01-3% migration, 48 h after injection 32 ). The interaction of CCR7 with CCL21 also controls lymphocyte migration from the blood into secondary lymphoid tissues through high endothelial venules 16, 34, 35 . Our results thus extend the understanding of the functions of CCR7, suggesting a unifying mechanism for the control of lymphocyte access to secondary lymphoid tissues, whether via high endothelial venules from the blood or via lymphatic endothelium and afferent lymph from peripheral tissues. Exit is likely to be as important as entry in controlling the accumulation of lymphocytes at peripheral sites. In this context, the importance of CCR7 in lymphocyte transit may help to explain observations of lymphocyte accumulation in the gastrointestinal tract, lung and body cavities of Ccr7 À/À mice (U.E. Höpken and M.L., unpublished data). In a mouse model of influenza, most influenza virus-specific interferon-g-positive CD4 + T cells in the lungs of actively infected mice are CCR7 À , but most bystander effector T cells (which produce interferon-g in response to polyclonal stimuli) are CCR7 + (ref. 26) . Moreover, antigen recognition transiently downregulates CCR7 function on T cells, at least in lymph nodes 36 . These data suggest that downregulation of CCR7 on actively responding effector T cells may help antigen-specific T cells accumulate at the peripheral sites of antigen recognition 37 while allowing bystander memory and effector T cells to exit rapidly and continue their immune surveillance elsewhere. Consistent with that idea, in vitroactivated CCR7-transgenic effector T cells show a deficit in pulmonary accumulation in asthma models associated with enhanced exit from the lung and migration into the draining mediastinal lymph nodes compared with that of control (CCR7 À ) T helper type 2 cells (S. Bromley and A. Luster, personal communication).
Of course, a substantial fraction of normal circulating memory and effector T cells lack detectable CCR7 expression even in the blood; these cells may be destined to enter but not leave tissue sites or may be able to upregulate the CCR7 'exit pass' after tissue entry. Future studies should characterize the regulation of CCR7 expression on different lymphocyte subsets during peripheral immune responses and evaluate the relevance of CCR7-regulated lymphocyte exit to the course of inflammation and the defense against pathogens.
In conclusion, we have shown that lymphocyte exit from tissues into lymph is selective and active and that CCR7 is key in this process. These findings fill a considerable gap in the understanding of the cycle of lymphocyte recirculation and identify tissue exit as a potential control point for the modulation of local inflammatory and immune responses.
METHODS
Animals, surgery and lymph cannulation. For cell transfer, sex-and agematched BALB/c Ccr7 À/À and wild-type mice were used. Donor mice for experiments comparing memory T cell exit were 6-9 months of age; those used for transduction were 6 weeks old. As recipients, 6-to 12-week-old BALB/c mice (Jackson Laboratories) or Thy-1.1-congenic BALB/c mice (a gift from I. Weissman, Stanford University, Stanford, California) were used. Randomly bred sheep (Central Animal Facility, University of Guelph, Ontario, Canada) or Cheviot wethers (Ovis) 8-10 months of age were used. For the collection of pseudoafferent lymph 38 , subiliac lymph nodes were surgically removed more than 4 weeks before lymph cannulation as described 38 . Afferent (popliteal) and pseudoafferent lymph vessels were cannulated, and lymph was collected over 12-hour periods as described 38 . The cannulated lymph vessels drained the skin, muscles and bones of the hind leg or the rear flank and abdomen 39 . All animal experiments were approved by local review boards (Veterans Affairs Palo Alto Health Care System Institutional Animal Care and Use Committee, Palo Alto, California; Stanford University Administrative Panel on Laboratory Animal Care, Stanford, California; South Dakota State University Institutional Animal Care and Use Committee, Brookings, South Dakota; and the University of Toronto Animal Care Committee, Toronto, Ontario, Canada), and were done according to institutional, federal, and state guidelines.
Cell isolation, PTX treatment, cell labeling and transfer. Cells were isolated from mouse lymph nodes and spleens as described 26 . Ovine lymphocytes from lymph were washed with RPMI 1640 medium containing 5% FCS and 25 mM HEPES, pKa 7.55. Ovine blood was collected from the jugular vein and was mixed with anticoagulant. Mononuclear cells were isolated from mouse spleen and ovine blood by gradient centrifugation with Histopaque (Sigma). In some experiments, the injected populations were enriched fivefold for CD8 + T cells by negative selection with CD19 microbeads (Miltenyi Biotec). For PTX treatment, splenocytes were incubated for 2 h at 37 1C with 200 ng/ml of PTX (Sigma) in RPMI 1640 medium containing 5% FCS and 25 mM HEPES, pKa 7.55. Cell labeling with PKH26 was done according to the manufacturer's instructions (Sigma). For CFSE (Molecular Probes) labeling, cells at a density of 5 Â 10 6 cells/ml were incubated for 5 min at 37 1C in 0.2 mM CFSE in HBSS containing 25 mM HEPES. PKH26 and CFSE labeling reactions were stopped by the addition of serum. Cells were subsequently washed three times with RPMI 1640 medium containing 5% FCS and 25 mM HEPES, pKa 7.55, followed by one PBS wash. Cells (1 Â 10 6 to 5 Â 10 6 in 10 ml PBS) were injected into the footpads of recipient mice. At 12 h after transfer, single-cell suspensions of the draining popliteal lymph nodes were analyzed for transferred cells (identified by fluorescent labels or Thy-1.2 congenic marker), and total cell numbers were determined by flow cytometry with a fixed number of polystyrene beads (Polybead; Polysciences). In experiments comparing the relative migration efficiency of Ccr7 À/À cells with that of wild-type cells of specific lymphocyte subsets (total lymphocytes, total CD4 + T cells, naive (CD45RB hi ) and memory (CD45RB lo ) CD4 + T cells, CD8 + T cells, and B cells), the ratio of migrated CFSE + cells (Ccr7 À/À in 'test mice'; wild-type in control mice) to PKH26 + cells (admixed wild-type cells as a common internal standard) of the various subsets was determined by flow cytometry. The migration of Ccr7 À/À cells relative to that of wild-type cells was determined by calculation of the ratios of migrated CFSE/PKH26 to injected CFSE/PKH26 cells in each lymphocyte subset. To control for variability in overall recovery, results were normalized to the mean ratio of CFSE + wild-type cells to PKH26 + wild-type cells for each subset (set as 100%). In different experiments, the injected wild-type and Ccr7 À/À populations consisted of 48-67% CD19 + B cells, 10% CD8 + (after enrichment) and 18-25% CD4 + , with 22-40% of the last being CD45RB lo cells.
Retroviral transduction.
A construct of sequence encoding human CCR7 upstream of an IRES-GFP cassette in MSCV 2.2b retroviral vector 40 was provided by D. Campbell (University of Washington, Seattle, Washington). Virus was produced as described 41 . Thy-1.2 + CD4 + T cells were isolated from spleens of wild-type and Ccr7 À/À mice with CD4 microbeads according to the manufacturer's instructions (Miltenyi Biotec) and were stimulated with platebound antibody to CD3 and antibody to CD28. At 24 h after stimulation, the cells were infected with CCR7 vector or control vector, as described 41 . On day 4 or 5 of culture, the cells were used for experiments.
Flow cytometry. Mouse or ovine cells were preincubated in rat IgG plus antibody to CD16 and CD32 (2.4G2, BD Pharmingen) or sheep IgG plus donkey IgG, respectively. Purified IgGs were purchased from Jackson Immunoresearch. Biotin-conjugated or fluorochrome-conjugated (phycoerythrin, peridinin chlorophyll-protein-cyanin 5.5, allophycocyanin, Alexa Fluor 647, phycoerythrin-cyanin 7 or fluorescein isothiocyanate) rat monoclonal antibodies recognizing the following mouse surface markers were used (all from BD Pharmingen): CD4 (RM4-5), CD45RB (16A), CD44 (IM7), CD19 (1D3), CD8 (53-6.7) and Thy-1.2 (30-H12). Alexa Fluor 405-labeled streptavidin (Molecular Probes) was used as a second-step reagent. Fluorochrome-conjugated mouse monoclonal antibodies recognizing the following ovine surface markers were used (all from Serotec): CD4 (44.38), CD8 (CC63) and CD45R (20.96) . In some experiments, unlabeled monoclonal antibodies were labeled with Zenon mouse antibody-labeling kits according to the manufacturer's instructions (Molecular Probes). Binding 26 of CCL19-Ig 17 was detected with biotinylated multispecies adsorbed F(ab¢) 2 donkey antibody to human IgG (Jackson Immunoresearch) followed by phycoerythrin-labeled streptavidin (BD Pharmingen). Specificity of the staining was demonstrated by blocking with excess unlabeled recombinant mouse CCL19 (R&D Systems) or staining with control immunoglobulin chimera (data not shown).
Chemotaxis assay. Single-cell suspensions were incubated for 1 h at 37 1C before the assay. Recombinant mouse CCL21 and human CCL19 (R&D Systems) were 'titrated' in triplicate between 1 and 300 nM. The assay was done in 24-well Transwell plates with a pore size of 5 mm (Corning Costar, obtained through Fisher Scientific) and was analyzed as described 26 .
